Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: Updated meta-analyses

BMJ (Online)

Volumn 363, Issue , 2018, Pages

  Arbyn, Marc ^a   Smith, Sara B ^b   Temin, Sarah ^c   Sultana, Farhana ^d,e   Castle, Philip ^b,f  

^a Belgian Cancer Centre   (Belgium)

^b Global Coalition Against Cervical Cancer   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e VICTORIAN CYTOLOGY SERVICE   (Australia)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GRADING; CANCER SCREENING; COLPOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERUS BIOPSY; VIRUS DETECTION; WART VIRUS; COMPLICATION; CYTOLOGY; EARLY CANCER DIAGNOSIS; GENETICS; IMMUNOLOGY; INCIDENCE; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROCEDURES; SPECIMEN HANDLING; STATISTICS AND NUMERICAL DATA; UTERINE CERVIX TUMOR; VAGINA; VAGINA SMEAR; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; INTENTION TO TREAT ANALYSIS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS; VAGINA; VAGINAL SMEARS;

EID: 85058318864     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.k4823     Document Type: Article

References (132)

1. Arbyn M, Castellsagué X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86. doi:10.1093/annonc/mdr015
2. Surveillance Epidemiology and End Results Program (SEER). Cancer Stat Facts: Cervical Cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/cervix.html
3. Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677-86. doi:10.1158/1055-9965.EPI-04-0569
4. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009;45:2640-8. doi:10.1016/j.ejca.2009.07.018
5. Arbyn M, Antoine J, Mägi M, et al. Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania. Int J Cancer 2011;128:1899-907. doi:10.1002/ijc.25525
6. Bray F, Lortet-Tieulent J, Znaor A, Brotons M, Poljak M, Arbyn M. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine 2013;31(Suppl 7):H32-45. doi:10.1016/j.vaccine.2013.02.071
7. IARC. Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10 IARCPress, 2005.
8. Sasieni P, Castanon A. Dramatic increase in cervical cancer registrations in young women in 2009 in England unlikely to be due to the new policy not to screen women aged 20-24. J Med Screen 2012;19:127-32. doi:10.1258/jms.2012.012081
9. Baldur-Felskov B, Munk C, Nielsen TS, et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012. Cancer Causes Control 2015;26:1105-16. doi:10.1007/s10552-015-0603-7
10. Finnish Cancer Registry. Cancer Statistics. Cancer Society of Finland. https://cancerregistry.fi/statistics/cancer-statistics/
11. Nationellt Kvalitetsregister för Cervixcancerprevention (NKCx). Swedish National Cervical Screening Registry Analysis. Annual reports (in Swedish). http://www.nkcx.se/templates/-rsrapport-2017.pdf
12. The Netherlands Cancer Registry. Dutch cancer figures. Integraal Kankercentrum Nederland. https://www.cijfersoverkanker.nl/
13. Laukkanen P, Koskela P, Pukkala E, et al. Time trends in incidence and prevalence of human papillomavirus type 6, and 11, 16 infections in Finland. J Gen Virol 2003;84:2105-9. doi:10.1099/vir.0.18995-0
14. Lehtinen M, Kaasila M, Pasanen K, et al. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. Int J Cancer 2006;119:2612-9. doi:10.1002/ijc.22131
15. Elit L, Saskin R, Raut R, Elliott L, Murphy J, Marrett L. Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort. Gynecol Oncol 2013;128:95-100. doi:10.1016/j.ygyno.2012.10.006
16. Ricardo-Rodrigues I, Jiménez-García R, Hernández-Barrera V, Carrasco-Garrido P, Jiménez-Trujillo I, López de Andrés A. Social disparities in access to breast and cervical cancer screening by women living in Spain. Public Health 2015;129:881-8. doi:10.1016/j.puhe.2015.02.021
17. Arbyn M, Fabri V, Temmerman M, Simoens C. Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002-2006). PLoS One 2014;9:e92615. doi:10.1371/journal.pone.0092615
18. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding HPV testing in secondary prevention of cervical cancer. Vaccine 2012;30(Suppl 5):F88-99. doi:10.1016/j.vaccine.2012.06.095
19. Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 2017;8:CD008587.
20. Ronco G, Dillner J, Elfström KM, et al, International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32. doi:10.1016/S0140-6736(13)62218-7
21. Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013;132:2223-36. doi:10.1002/ijc.27790
22. Arbyn M, Verdoodt F, Snijders PJF, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;15:172-83. doi:10.1016/S1470-2045(13)70570-9
23. Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJF, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer 2015;51:2375-85. doi:10.1016/j.ejca.2015.07.006
24. Racey CS, Withrow A, Gesink D. Self-collected HPV Testing Improves Participation in Cervical Cancer Screening: A Systematic Review and Meta-analysis. Can.J.Public Health 2013;104:e159-66.
25. Curry SJ, Krist AH, Owens DK, et al, US Preventive Services Task Force. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018;320:674-86. doi:10.1001/jama.2018.10897
26. Tranberg M, Bech BH, Blaakær J, Jensen JS, Svanholm H, Andersen B. Preventing cervical cancer using HPV self-sampling: direct mailing of test-kits increases screening participation more than timely opt-in procedures -A randomized controlled trial. BMC Cancer 2018;18:273. doi:10.1186/s12885-018-4165-4
27. Chao YS, Clark M, Ford C. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence . Canadian Agency for Drugs and Technologies in Health, 2018.
28. Arbyn M, Snijders PJ, Meijer CJLM, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect 2015;21:817-26. doi:10.1016/j.cmi.2015.04.015
29. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36. doi:10.7326/0003-4819-155-8-201110180-00009
30. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. doi:10.1136/bmj.d5928
31. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151:264-9.
32. Deeks JJ, Bossuyt PM, Gatsonis C. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2013.
33. Harbord RM, Deeks JJ, Egger M, Whiting P, Sterne JA. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007;8:239-51. doi:10.1093/biostatistics/kxl004
34. Harbord RM, Whiting P. metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J 2009;9:211-29.
35. Takwoingi Y, Deeks J. METADAS: A SAS macro for meta-analysis of diagnostic accuracy studies. Quick reference and worked example. https://methods.cochrane.org/sites/methods.cochrane.org.sdt/files/public/uploads/MetaDAS%20Quick%20Reference%20v1.3%20 May%202012.pdf
36. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-93. doi:10.1016/j.jclinepi.2005.01.016
37. Harbord RM, Harris RJ, Sterne JAC. Updated tests for small-study effects in meta-analyses. Stata J 2009;9:197-210.
38. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 2014;72:39. doi:10.1186/2049-3258-72-39
39. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. doi:10.1136/bmj.327.7414.557
40. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. metan: fixed-and random-effects meta-analysis. Stata J 2008;8:3-28.
41. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. doi:10.1016/0197-2456(86)90046-2
42. Harbord R, Higgins JP. Meta-regression in Stata. Stata J 2013;8:493-519.
43. Zhao FH, Jeronimo J, Qiao YL, et al. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila) 2013;6:938-48. doi:10.1158/1940-6207. CAPR-13-0091
44. Chernesky M, Jang D, Gilchrist J, et al. Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples. Sex Transm Dis 2014;41:365-8. doi:10.1097/OLQ.0000000000000125
45. Hesselink AT, Berkhof J, van der Salm ML, et al. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol 2014;52:890-6. doi:10.1128/JCM.03195-13
46. Jeronimo J, Bansil P, Lim J, et al. A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer 2014;24:576-85. doi:10.1097/IGC.0000000000000084
47. Wang SM, Hu SY, Chen F, et al. Clinical evaluation of human papillomavirus detection by careHPV? test on physician-samples and self-samples using the indicating FTA Elute® card. Asian Pac J Cancer Prev 2014;15:7085-90. doi:10.7314/APJCP.2014.15.17.7085
48. Zhang S, Kang L, Liu B, et al. [Evaluation of screening performance of HPV DNA test on specimens from different sites of the female genital tract]. Zhonghua Zhong Liu Za Zhi 2014;36:389-93.
49. Boggan JC, Walmer DK, Henderson G, et al. Vaginal Self-Sampling for Human Papillomavirus Infection as a Primary Cervical Cancer Screening Tool in a Haitian Population. Sex Transm Dis 2015;42:655-9. doi:10.1097/OLQ.0000000000000345
50. Porras C, Hildesheim A, Gonzalez P, et al. Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. J Natl Cancer Inst 2014;107:400. doi:10.1093/jnci/dju400
51. Chen Q, Du H, Zhang R, et al, Evaluation of novel assays for the detection of human papilloma virus in self-collected samples for cervical cancer screening. Genet Mol Res 2016; 15. doi
52. Chen K, Ouyang Y, Hillemanns P, Jentschke M. Excellent analytical and clinical performance of a dry self-sampling device for human papillomavirus detection in an urban Chinese referral population. J Obstet Gynaecol Res 2016;42:1839-45. doi:10.1111/jog.13132
53. Jentschke M, Chen K, Arbyn M, et al. Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections. J Clin Virol 2016;82:46-50. doi:10.1016/j.jcv.2016.06.016
54. Qin Y, Zhang H, Marlowe N, et al. Evaluation of human papillomavirus detection by Abbott m2000 system on samples collected by FTA Elute? Card in a Chinese HIV-1 positive population. J Clin Virol 2016;85:80-5. doi:10.1016/j.jcv.2016.11.002
55. Stanczuk G, Baxter G, Currie H, et al. Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway-PaVDaG study). BMJ Open 2016;6:e010660. doi:10.1136/bmjopen-2015-010660
56. Aiko KY, Yoko M, Saito OM, et al. Accuracy of self-collected human papillomavirus samples from Japanese women with abnormal cervical cytology. J Obstet Gynaecol Res 2017;43:710-7. doi:10.1111/jog.13258
57. Asciutto KC, Henningsson AJ, Borgfeldt H, Darlin L, Borgfeldt C. Vaginal and Urine Self-sampling Compared to Cervical Sampling for HPV-testing with the Cobas 4800 HPV Test. Anticancer Res 2017;37:4183-7.
58. Catarino R, Vassilakos P, Bilancioni A, et al. Accuracy of self-collected vaginal dry swabs using the Xpert human papillomavirus assay. PLoS One 2017;12:e0181905. doi:10.1371/journal.pone.0181905
59. Leeman A, Del Pino M, Molijn A, et al. HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: crosssectional data from a triage population. BJOG 2017;124:1356-63. doi:10.1111/1471-0528.14682
60. Asciutto KC, Ernstson A, Forslund O, Borgfeldt C. Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. J Clin Virol 2018;101:69-73. doi:10.1016/j.jcv.2018.02.002
61. Leinonen MK, Schee K, Jonassen CM, et al. Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions. J Clin Virol 2018;99-100:22-30. doi:10.1016/j.jcv.2017.12.008
62. Enerly E, Bonde J, Schee K, Pedersen H, Lönnberg S, Nygord M. Self-Sampling for Human Papillomavirus Testing among Non-Attenders Increases Attendance to the Norwegian Cervical Cancer Screening Programme. PLoS One 2016;11:e0151978. doi:10.1371/journal. pone.0151978
63. Moses E, Pedersen HN, Mitchell SM, et al. Uptake of communitybased, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: preliminary results of a randomised controlled trial. Trop Med Int Health 2015;20:1355-67. doi:10.1111/tmi.12549
64. Racey CS, Gesink DC, Burchell AN, Trivers S, Wong T, Rebbapragada A. Randomized Intervention of Self-Collected Sampling for Human Papillomavirus Testing in Under-Screened Rural Women: Uptake of Screening and Acceptability. J Womens Health (Larchmt) 2016;25:489-97. doi:10.1089/jwh.2015.5348
65. Sultana F, English DR, Simpson JA, et al. Home-based HPV selfsampling improves participation by never-screened and underscreened women: Results from a large randomized trial (iPap) in Australia. Int J Cancer 2016;139:281-90. doi:10.1002/ijc.30031
66. Zehbe I, Jackson R, Wood B, et al. Community-randomised controlled trial embedded in the Anishinaabek Cervical Cancer Screening Study: human papillomavirus self-sampling versus Papanicolaou cytology. BMJ Open 2016;6:e011754. doi:10.1136/bmjopen-2016-011754
67. Kitchener H, Gittins M, Cruickshank M, et al. A cluster randomized trial of strategies to increase uptake amongst young women invited for their first cervical screen: The STRATEGIC trial. J Med Screen 2018;25:88-98. doi:10.1177/0969141317696518
68. Modibbo F, Iregbu KC, Okuma J, et al. Randomized trial evaluating self-sampling for HPV DNA based tests for cervical cancer screening in Nigeria. Infect Agent Cancer 2017;12:11. doi:10.1186/s13027-017-0123-z
69. Kellen E, Benoy I, Vanden Broeck D, et al. A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non-participants in the Flemish cervical cancer screening program. Int J Cancer 2018;143:861-8. doi:10.1002/ijc.31391
70. Morrison EAB, Goldberg GL, Hagan RJ, Kadish AS, Burk RD. Selfadministered home cervicovaginal lavage: a novel tool for the clinical-epidemiologic investigation of genital human papillomavirus infections. Am J Obstet Gynecol 1992;167:104-7. doi:10.1016/S0002-9378(11)91637-8
71. Hillemanns P, Kimmig R, Hüttemann U, Dannecker C, Thaler CJ. Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet 1999;354:1970. doi:10.1016/S0140-6736(99)04110-0
72. Sellors JW, Lorincz AT, Mahony JB, et al. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. CMAJ 2000;163:513-8.
73. Wright TCJr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000;283:81-6. doi:10.1001/jama.283.1.81
74. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001;83:439-44. doi:10.1006/gyno.2001.6370
75. Lorenzato FR, Singer A, Ho L, et al. Human papillomavirus detection for cervical cancer prevention with polymerase chain reaction in self-collected samples. Am J Obstet Gynecol 2002;186:962-8. doi:10.1067/mob.2002.122390
76. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 2002;55:435-9. doi:10.1136/jcp.55.6.435
77. Garcia F, Barker B, Santos C, et al. Cross-sectional study of patientand physician-collected cervical cytology and human papillomavirus. Obstet Gynecol 2003;102:266-72.
78. Salmerón J, Lazcano-Ponce E, Lorincz A, et al. Comparison of HPVbased assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 2003;14:505-12. doi:10.1023/A:1024806707399
79. Brink AA, Meijer CJLM, Wiegerinck MA, et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006;44:2518-23. doi:10.1128/JCM.02440-05
80. Daponte A, Pournaras S, Mademtzis I, et al. Evaluation of HPV 16 PCR detection in self-compared with clinician-collected samples in women referred for colposcopy. Gynecol Oncol 2006;103:463-6. doi:10.1016/j.ygyno.2006.03.021
81. Girianelli VR, Thuler LC, Szklo M, et al. Comparison of human papillomavirus DNA tests, liquid-based cytology and conventional cytology for the early detection of cervix uteri cancer. Eur J Cancer Prev 2006;15:504-10. doi:10.1097/01.cej.0000220630.08352.7a
82. Holanda FJr, Castelo A, Veras TM, de Almeida FM, Lins MZ, Dores GB. Primary screening for cervical cancer through self sampling. Int J Gynaecol Obstet 2006;95:179-84. doi:10.1016/j.ijgo.2006.07.012
83. Seo SS, Song YS, Kim JW, Park NH, Kang SB, Lee HP. Good correlation of HPV DNA test between self-collected vaginal and clinician-collected cervical samples by the oligonucleotide microarray. Gynecol Oncol 2006;102:67-73. doi:10.1016/j.ygyno.2005.11.030
84. Szarewski A, Cadman L, Mallett S, et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen 2007;14:34-42. doi:10.1258/096914107780154486
85. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervicalcancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-36. doi:10.1016/S1470-2045(08)70210-9
86. Bhatla N, Dar L, Patro AR, et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physiciancollected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol 2009;33:446-50. doi:10.1016/j.canep.2009.10.013
87. Balasubramanian A, Kulasingam SL, Baer A, et al. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis 2010;14:185-95. doi:10.1097/LGT.0b013e3181cd6d36
88. Gustavsson I, Sanner K, Lindell M, et al. Type-specific detection of high-risk human papillomavirus (HPV) in self-sampled cervicovaginal cells applied to FTA elute cartridge. J Clin Virol 2011;51:255-8. doi:10.1016/j.jcv.2011.05.006
89. Taylor S, Wang C, Wright TC, Denny L, Kuhn L. A comparison of human papillomavirus testing of clinician-collected and selfcollected samples during follow-up after screen-and-treat. Int J Cancer 2011;129:879-86. doi:10.1002/ijc.25731
90. Twu NF, Yen MS, Lau HY, Chen YJ, Yu BK, Lin CY. Type-specific human papillomavirus DNA testing with the genotyping array: a comparison of cervical and vaginal sampling. Eur J Obstet Gynecol Reprod Biol 2011;156:96-100. doi:10.1016/j.ejogrb.2010.12.023
91. Belinson JL, Du H, Yang B, et al. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int J Cancer 2012;130:1855-60. doi:10.1002/ijc.26202
92. Dijkstra MG, Heideman DA, van Kemenade FJ, et al. Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. J Clin Virol 2012;54:147-51. doi:10.1016/j.jcv.2012.02.022
93. Longatto-Filho A, Naud P, Derchain SF, et al. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology. Virchows Arch 2012;460:577-85. doi:10.1007/s00428-012-1242-y
94. van Baars R, Bosgraaf RP, ter Harmsel BW, Melchers WJG, Quint WG, Bekkers RL. Dry storage and transport of a cervicovaginal self-sample using the Evalyn Brush(R): reliable HPV detection combined with women's comfort. J Clin Microbiol 2012;50:3937-43. doi:10.1128/JCM.01506-12
95. Zhao FH, Lewkowitz AK, Chen F, et al. Pooled analysis of a selfsampling HPV DNA Test as a cervical cancer primary screening method. J Natl Cancer Inst 2012;104:178-88. doi:10.1093/jnci/djr532
96. Darlin L, Borgfeldt C, Forslund O, Hénic E, Dillner J, Kannisto P. Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. J Clin Virol 2013;56:52-6. doi:10.1016/j.jcv.2012.09.002
97. Geraets DT, van Baars R, Alonso I, et al. Clinical evaluation of highrisk HPV detection on self-samples using the indicating FTA-elute solid-carrier cartridge. J Clin Virol 2013;57:125-9. doi:10.1016/j.jcv.2013.02.016
98. Guan Y, Gravitt PE, Howard R, et al. Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens. J Virol Methods 2013;189:167-71. doi:10.1016/j.jviromet.2012.11.010
99. Jentschke M, Soergel P, Hillemanns P. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples. J Virol Methods 2013;193:131-4. doi:10.1016/j.jviromet.2013.05.009
100. Jentschke M, Lange V, Soergel P, Hillemanns P. Enzyme-linked immunosorbent assay for p16(INK4a) -A new triage test for the detection of cervical intraepithelial neoplasia? Acta Obstet Gynecol Scand 2013;92:160-4. doi:10.1111/aogs.12032
101. Nieves L, Enerson CL, Belinson S, et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Int J Gynecol Cancer 2013;23:513-8. doi:10.1097/IGC.0b013e318280f3bc
102. Bais AG, van Kemenade FJ, Berkhof J, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007;120:1505-10. doi:10.1002/ijc.22484
103. Gök M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ 2010;340:c1040. doi:10.1136/bmj.c1040
104. Giorgi Rossi P, Marsili LM, Camilloni L, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer 2011;104:248-54. doi:10.1038/sj.bjc.6606040
105. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011;378:1868-73. doi:10.1016/S0140-6736(11)61522-5
106. Piana L, Leandri FX, Le RL, Heid P, Tamalet C, Sancho-Garnier H. L'auto-prélèvement vaginal à domicile pour recherche de papilloma virus à haut risque. Une solution de remplacement pour les femmes ne participant pas au dépistage cytologique des cancers du col de l'utérus. Campagne expérimentale du département des Bouches-du-Rhône. Bull Cancer 2011;98:723-31.
107. Szarewski A, Cadman L, Mesher D, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening -A randomised controlled trial. Br J Cancer 2011;104:915-20. doi:10.1038/bjc.2011.48
108. Virtanen A, Nieminen P, Luostarinen T, Anttila A. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev 2011;20:1960-9. doi:10.1158/1055-9965.EPI-11-0307
109. Wikström I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer 2011;105:337-9. doi:10.1038/bjc.2011.236
110. Gök M, van Kemenade FJ, Heideman DA, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer 2012;130:1128-35. doi:10.1002/ijc.26128
111. Darlin L, Borgfeldt C, Forslund O, et al. Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. J Clin Virol 2013;58:155-60. doi:10.1016/j.jcv.2013.06.029
112. Sancho-Garnier H, Tamalet C, Halfon P, et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer 2013;133:2681-7.
113. Broberg G, Gyrd-Hansen D, Miao Jonasson J, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer 2014;134:2223-30. doi:10.1002/ijc.28545
114. Cadman L, Wilkes S, Mansour D, et al. A randomized controlled trial in non-responders from Newcastle upon Tyne invited to return a self-sample for Human Papillomavirus testing versus repeat invitation for cervical screening. J Med Screen 2015;22:28-37. doi:10.1177/0969141314558785
115. Haguenoer K, Sengchanh S, Gaudy-Graffin C, et al. Vaginal selfsampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trial. Br J Cancer 2014;111:2187-96. doi:10.1038/bjc.2014.510
116. Arrossi S, Thouyaret L, Herrero R, et al. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. Lancet Glob Health 2015;3:e85-94. doi:10.1016/S2214-109X(14)70354-7
117. Giorgi Rossi P, Fortunato C, Barbarino P, et al. Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter. Br J Cancer 2015;112:667-75. doi:10.1038/bjc.2015.11
118. Schee K, Stefan L, Pedersen H, Bonde J, Nyganullrd M. Improving attendance to the cervical cancer screening program: Does self-sampling at home improve cervical cancer prevention. Cancer Res 2014;74(Suppl 19):4135. doi:10.1158/1538-7445. AM2014-4135
119. Arbyn M, Peeters E, Benoy I, et al. VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. J Clin Virol 2018;107:52-6. doi:10.1016/j.jcv.2018.08.006
120. Snellenberg S, De Strooper LM, Hesselink AT, et al. Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMC Cancer 2012;12:551. doi:10.1186/1471-2407-12-551
121. Cuschieri K, Ronco G, Lorincz A, et al. Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer 2018;143:735-45. doi:10.1002/ijc.31261
122. Vorsters A, Van den Bergh J, Micalessi I, et al. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur J Clin Microbiol Infect Dis 2014;33:2005-14. doi:10.1007/s10096-014-2147-2
123. Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ 2014;349:g5264. doi:10.1136/bmj.g5264
124. Van Keer S, Tjalma WAA, Pattyn J, et al. Human papillomavirus genotype and viral load agreement between paired first-void urine and clinician-collected cervical samples. Eur J Clin Microbiol Infect Dis 2018;37:859-69. doi:10.1007/s10096-017-3179-1
125. Sanner K, Wikström I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer 2009;101:871-4. doi:10.1038/sj.bjc.6605194
126. Lam JU, Rebolj M, Møller Ejegod D, et al. Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms. Int J Cancer 2017;140:2212-9. doi:10.1002/ijc.30647
127. Baussano I, Tshering S, Choden T, et al. Cervical cancer screening in rural Bhutan with the careHPV test on self-collected samples: an ongoing cross-sectional, population-based study (REACH-Bhutan). BMJ Open 2017;7:e016309. doi:10.1136/bmjopen-2017-016309
128. Stanczuk GA, Baxter GJ, Currie H, et al. Defining optimal triage strategies for hrHPV screen positive women -an evaluation of HPV 16/18 genotyping, cytology and p16/Ki-67 cyto-immunochemistry. Cancer Epidemiol Biomarkers Prev 2017;26:1629-35. doi:10.1158/1055-9965.EPI-17-0534
129. Saville M, Hawkes D, Mclachlan E, Anderson S, Arabena K. Selfcollection for under-screened women in a National Cervical Screening Program: pilot study. Curr Oncol 2018;25:27-32. doi:10.3747/co.25.3915
130. McLachlan E, Anderson S, Hawkes D, Saville M, Arabena K. Completing the cervical screening pathway: Factors that facilitate the increase of self-collection uptake among under-screened and never-screened women, an Australian pilot study. Curr Oncol 2018;25:17-26. doi:10.3747/co.25.3916
131. Gustavsson I, Aarnio R, Berggrund M, et al. Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology. Br J Cancer 2018;118:896-904. doi:10.1038/bjc.2017.485
132. Polman NJ, Berkhof J. IMPROVE-study: Prospective randomized pilot implementation trial of HPV self-sampling in primary cervical screening. http://www.trialregister.nl/trialreg/admin/rctview. asp?TC=5078.